Skip to main content

Table 2 Heritability of talinolol clearance (50 mg dose) according to structural equation modeling

From: Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters

Model

A

D

C

E

Chi2

p

AIC

 

(95 % CI)

(95 % CI)

(95 % CI)

(95 % CI)

   

Saturated

-

-

-

-

-

-

63.67

ACE

0.00

(0.00–0.00)

-

0.535

(0.346–0.724)

0.465

(0.276–0.654)

36.9

0.001

70.60

ADE

0.500

(0.282–0.717)

0.00

(0.00–0.00)

-

0.500

(0.282–0.717)

39.6

<0.001

73.30

AE

0.500

(0.282–0.717)

-

-

0.500

(0.282–0.717)

39.6

<0.001

71.30

CE

-

-

0.535

(0.346–0.724)

0.465

(0.276–0.654)

37.9

0.002

68.60

  1. A additive genetic effects, D dominant genetic effects, C common environmental effects, E unique environmental effects, 95 % CI 95 % confidence interval, Chi2 chi-square value, AIC Akaike information criterion. P values were calculated with respect to the saturated model. The best fitting model (CE, bold text) was chosen based on the lowest AIC